← Trials/Trial dossier/NCT00104442

CompletedPhase 4

Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Lead sponsor

Novartis

Asset

Rivastigmine

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•Study partner/caregiver required

Primary endpoint

•Changes in specific brain enzyme activity

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCENA713BUS25

NCT IDNCT00104442

Timeline

Milestones

Study start2003-10 (month precision)

Study first posted2005-03-01estimated

Study completion2006-04actual (month precision)

Last update posted2007-12-21estimated

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of mild to moderate Alzheimer's disease

•Must be able to swallow capsule/tablet

•Must have a caregiver who is available to attend all study visits

Exclusion criteria

•Digestive problems related to peptic ulcer

•Experienced a heart attack or stroke in the last 6 months

•Serious/unstable asthma or severe pulmonary (lung) disease

•On current treatment with a blood thinner

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Behavior / neuropsychiatric

1 endpoint

Secondary/protocol endpoint

Correlate changes in specific brain enzyme activity at week 13 to cognition and behavior

descriptive

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

Changes in specific brain enzyme activity from baseline to week 13

descriptive

Secondary/protocol endpoint/low confidence

Changes in levels of protein biomarkers in Alzheimer's disease and neurodegeneration from baseline to week 13

ratio, descriptive

Secondary/protocol endpoint/low confidence

Correlate changes in specific brain enzyme activity after 13 weeks treatment to changes in global functioning at 13 and 26 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.